OncologyTier 2Topic

Rationale, accuracy, benefits, and harms of screening tests

Trade-offs

Every diagnostic and screening test in oncology carries trade-offs between benefit (earlier/more accurate diagnosis) and harm (false positives, overdiagnosis, procedural risk, cost/anxiety) - understanding these principles is central to appropriate test selection and interpreting results
Population-level cancer screening programs are only justified when the aggregate benefit (mortality reduction) outweighs the aggregate harm across the screened population, not simply based on individual anecdote

Sensitivity/specificity describe test performance against a fixed disease state; positive/negative predictive value depend additionally on disease prevalence in the population being tested - the same test performs very differently as a population screen (low prevalence, poor PPV) versus in a high-risk diagnostic workup (higher prevalence, better PPV)
Lead-time bias - earlier detection appears to prolong survival from diagnosis even if it does not delay death at all, simply by moving the diagnosis date earlier - a key reason raw "5-year survival" statistics can mislead when evaluating screening benefit
Overdiagnosis - detecting a cancer that would never have caused symptoms or death within the patient's lifetime, exposing them to the harms of treatment without any possible benefit

Randomised controlled trials with disease-specific mortality (not just earlier detection or 5-year survival) as the endpoint are needed to properly evaluate a screening test's true benefit, given how misleading lead-time bias and overdiagnosis can be with softer endpoints

Screening program design (interval, starting age, population selected) is calibrated to maximise the benefit-to-harm ratio for that specific population, which is why recommendations differ by age, sex, and risk factors rather than applying uniformly to everyone

Prostate-specific antigen screening (a frequently cited example of a test with a substantial overdiagnosis problem), mammography, lung cancer CT screening in high-risk smokers

A test can have excellent sensitivity and specificity and still cause net population harm if overdiagnosis/overtreatment of indolent disease outweighs the benefit of detecting genuinely lethal disease earlier - this is why "more testing" is not automatically better, and why screening recommendations are more nuanced than simple test accuracy alone

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.